Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26253259 | 1.00 | FBP1 (0.33) | FBP1 | |
| SCHEMBL13882141 | 0.91 | FBP1 (0.33) | FBP1 | |
| SCHEMBL13882144 | 0.86 | FBP1 (0.31) | FBP1 | |
| SCHEMBL17445985 | 0.84 | — | — | |
| SCHEMBL17445995 | 0.84 | — | — | |
| SCHEMBL25768995 | 0.83 | — | — | |
| SCHEMBL26253261 | 0.83 | — | — | |
| SCHEMBL12667501 | 0.81 | — | — | |
| SCHEMBL12223697 | 0.81 | — | — | |
| SCHEMBL25553231 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018496-A1 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | INTELLIA THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230383252-A1 | Natural Killer Cell Receptor 2B4 Compositions and Methods for Immunotherapy | INTELLIA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11795460-B2 | Compositions and methods for TTR gene editing and treating ATTR amyloidosis | INTELLIA THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230295587-A1 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | INTELLIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230212575-A1 | Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency | INTELLIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018496-A1 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | KLKB1, KLK1, KLK2 | FBP1 2283/4885 |
| US-20230383252-A1 | Natural Killer Cell Receptor 2B4 Compositions and Methods for Immunotherapy | KLRK1, HAVCR2, MICA | FBP1 4212/4885 |
| US-20230295587-A1 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | KLKB1, KLK1, KLK2 | FBP1 2283/4885 |
| US-11795460-B2 | Compositions and methods for TTR gene editing and treating ATTR amyloidosis | TTR, APOB, CRYAA | FBP1 3028/4885 |
| US-20230212575-A1 | Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency | SERPINA2, SERPINB1, SERPINE1 | FBP1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.